Cardiac masses are rare, but remain an important component of cardio-oncology practice.
These include benign tumors, malignant tumors (primary and secondary) and tumor-like …

CD19-specific chimeric antigen receptor (CAR) T cell therapies have shown remarkable
early success in highly refractory and relapsing hematological malignancies. However, this …

Due to its poor capacity for regeneration, the heart is particularly sensitive to the loss of
contractile cardiomyocytes. The onslaught of damage caused by ischaemia and reperfusion, …

In a previously published cohort profile, 1 we showed how the MRC National Survey of
Health and Development (NSHD), the oldest of the British birth cohort studies, has played an …

The population of patients with cancer is rapidly expanding, and the diagnosis and monitoring
of cardiovascular complications greatly rely on imaging. Numerous advances in the field …

Canids display a wide diversity of social systems, from solitary to pairs to packs, and hence,
they have been extensively used as model systems to understand social dynamics in natural …

Cardiovascular disease and cancer are leading contributors to the global disease burden.
As a result of cancer therapy-related cardiotoxicities, cardiovascular disease results in …

The subspecialty of cardio-oncology aims to reduce cardiovascular morbidity and mortality
in patients with cancer or following cancer treatment. Cancer therapy can lead to a variety of …

Chimeric antigen receptor (CAR) T cell therapy is approved in the United States for the
treatment of acute lymphocytic leukemia and aggressive B cell lymphomas. Multiple …

Aim Cross-sectional studies reported associations between short leucocyte telomere length
(LTL) and measures of vascular and cardiac damage. However, the contribution of LTL …